Prevalence rate of Apgar score<75mins during the study period*
| Period | Control | Intervention 1 | Intervention 2 | Intervention 3 | Follow-up 1 | Follow-up 2 |
| Overall | ||||||
| Apgar<75 (n) | 189 | 215 | 208 | 224 | 227 | 228 |
| Births (n) | 14 342 | 15 425 | 13 905 | 14 664 | 13 857 | 14 321 |
| Prevalence, 95% CI | 1.32 (1.14 to 1.52) | 1.39 (1.22 to 1.59) | 1.50 (1.31 to 1.71) | 1.53 (1.34 to 1.74) | 1.64 (1.44 to 1.86) | 1.59 (1.40 to 1.81) |
| Intention-to-treat: Intervention as per randomisation | ||||||
| Unexposed | ||||||
| Apgar<75mins (n) | 189 | 147 | 52 | |||
| Births (n) | 14 342 | 10 619 | 4540 | |||
| Prevalence, 95% CI | 1.32 (1.14 to 1.52) | 1.38 (1.12 to 1.62) | 1.14 (0.87 to 1.50) | – | – | – |
| Exposed | ||||||
| Apgar<75mins (n) | 68 | 156 | 224 | 227 | 228 | |
| Births (n) | 4806 | 9365 | 14 664 | 13 857 | 14 321 | |
| Prevalence, 95% CI | – | 1.41 (1.11 to 1.79) | 1.67 (1.42 to 1.95) | 1.53 (1.34 to 1.74) | 1.64 (1.44 to 1.86) | 1.59 (1.40 to 1.81) |
| ‘ As-implemented ’ : Intervention as per first training | ||||||
| Unexposed | ||||||
| Apgar<75mins (n) | 189 | 184 | 124 | 87 | 51 | 21 |
| Births (n) | 14 342 | 14 293 | 9 040 | 6 641 | 2 839 | 1 306 |
| Prevalence, 95% CI | 1.32 (1.14 to 1.52) | 1.29 (1.11 to 1.49) | 1.37 (1.15 to 1.63) | 1.31 (1.06 to 1.61) | 1.80 (1.37 to 2.36) | 1.61 (1.05 to 2.45) |
| Exposed | ||||||
| Apgar<75mins (n) | 31 | 84 | 137 | 176 | 207 | |
| Births (n) | 1 132 | 4 865 | 8 023 | 11 018 | 13 015 | |
| Prevalence, 95% CI | – | 2.74 (1.93 to 3.87) | 1.73 (1.40 to 2.13) | 1.71 (1.45 to 2.01) | 1.60 (1.38 to 1.85) | 1.59 (1.38 to 1.82) |
*Based on the 86 514 births with an assigned Apgar score observed in the 12 maternity units which had attended the THISTLE Study Train the Trainer (T3) programme and had not implemented the intervention prior to the study (two units declined to participate during the study period).